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Abstract
Background: While peripheral neuropathy is a common side effect of platinum-based chemotherapy, central nervous
system (CNS) toxicity, such as encephalopathy or seizures, appears to be rare. This manuscript describes the only
reported case of nonconvulsive status epilepticus associated with cisplatin in a cervical cancer patient who does not
have other underlying medical conditions.
Case presentation: The patient is a 54-year-old Chinese female with recurrent stage IIIB moderately differentiated
squamous cell carcinoma of the cervix who was being treated with cisplatin and topotecan. During the sixth cycle
of this regimen, the patient presented with mental status changes. While imaging and laboratory values were within
normal limits, the patient’s EEG revealed nonconvulsive status epilepticus. After appropriate intervention, she made a
complete recovery with no further seizures. The patient currently remains on antiepileptic therapy, but is no longer
receiving cisplatin.
Conclusion: Patients who present with new onset seizures should primarily be evaluated for underlying medical
conditions. Among patients who are suspected to have CNS side effects associated with platinum use, we recommend
avoidance of platinum agents in future chemotherapeutic regimens. Although rare, providers should be aware of the
potential for CNS toxicity associated with this drug class.
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Background
Platinum analogs are chemotherapeutic agents used to
treat a wide variety of malignancies. Members of this
drug class commonly prescribed for gynecologic malig-
nancies include cisplatin and carboplatin. These medica-
tions work by covalently binding to DNA to produce
intrastrand and interstrand crosslinks. The formation of
these DNA adducts leads to inhibition of transcription
and replication, as well as cell-cycle arrest [1].
The most common side effects associated with platinum
agents are nephrotoxicity, myelosuppression, nausea and
vomiting, and hypersensitivity reactions. Neurotoxicity is
also reported, though the frequency varies widely among
the drugs in this class. While up to 60 % of patients
receiving cisplatin have neurotoxicity, only 4-5 % of patients
who receive carboplatin experience this side effect [2].
Peripheral neuropathy is the most common neurological
toxicity associated with platinum agents. Patients with
platinum-induced peripheral neuropathy can experience
paresthesia in a “glove and stocking” distribution, loss of
vibratory sensation, and loss of proprioception that can
severely affect activities of daily living and quality of life.
Ototoxicity, in the form of hearing loss or tinnitus, is also
a well-described neurological side effect associated with
cisplatin. Encephalopathy, transient blindness, aphasia,
and seizures are reported to be associated with platinum
use, but appear to be exceedingly rare in the absence of
brain pathology, laboratory abnormalities, or medication
overdose [3–5].
In this paper, we report a case of status epilepticus as-
sociated with cisplatin in a patient with recurrent cer-
vical carcinoma.
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Case presentation
The patient is a 54-year-old female with recurrent stage
IIIB moderately differentiated squamous cell carcinoma
of the cervix. Patient had no relevant prior medical or
family history. Her initial treatment included one cycle of
oxaliplatin and tegafur followed by intensity-modulated
radiotherapy (IMRT) and vaginal brachytherapy. At com-
pletion of her radiation, the patient received five cycles of
taxane and platinum-based chemotherapy with a complete
response. She remained without evidence of disease for
two years, when she was diagnosed with a recurrence in
her retroperitoneal and thoracic lymph nodes. Oxaliplatin
and paclitaxel were initiated, but discontinued after one
cycle due to vague “mental status changes.” She under-
went brain imaging at that time that was within normal
limits. She was then treated with radiation to the retro-
peritoneal lymph nodes followed by immunotherapy with
dendritic cell and cytokine-induced killer cell transfusions
resulting in a partial response. The patient was then initi-
ated on an oral taxane for two cycles with persistent
disease. She then presented to our institution and was dis-
positioned to topotecan (0.75 mg/m2) daily on cycle days
one, two, and three and cisplatin (50 mg/m2) on cycle day
1, administered every three weeks. The patient tolerated
the first five cycles without incident and achieved an
objective tumor response. However, on day two of
cycle six, she developed altered mental status and was
not responding appropriately to questions or com-
mands. She was brought to the emergency room where
vital signs and laboratory values, including complete
blood count, complete metabolic panel, and urinalysis,
were within normal limits. Neurological examination
revealed no focal deficits. She underwent CT and MRI
of the brain, which were also within normal limits.
However, electroencephalogram (EEG) revealed the pres-
ence of nonconvulsive seizures (NCS). She was given a
one-time dose of lorazepam with significant improvement
in her mental status. The patient was also initiated on le-
vetiracetam. A repeat EEG three days later noted reso-
lution of the seizure activity. After this episode, the patient
was transitioned to topotecan and bevacizumab with no
further seizures to date. Please reference Table 1 for time-
line of events.
Conclusions
This case describes the unusual presentation of a patient
in nonconvulsive status epilepticus attributed to cisplatin
use. As the patient had normal laboratory and imaging
findings without convulsions, the diagnosis was somewhat
more challenging. Interestingly, the patient reported a
history of vague mental status changes with platinum use
in the past. On further questioning, it appears that her
symptoms at that time were very similar to her current
presentation. However, she did not undergo EEG evalu-
ation or further neurological work-up.
While central nervous system (CNS) disorders are not
frequently associated with platinum use, cases have been
reported [3–6]. Posterior reversible encephalopathy syn-
drome (PRES) is the most commonly described platinum-
associated CNS toxicity in the literature [7]. PRES can
occur in a wide variety of clinical settings, including
eclampsia, sepsis, autoimmune disease, and medication-
related toxicity. Symptoms of PRES typically involve head-
ache, visual changes, seizures, and encephalopathy. PRES
is diagnosed by clinical presentation as well as brain MRI,
where white matter edema of the posterior cerebral hemi-
spheres is typically seen. When PRES is associated with
platinum drugs, symptoms have been reported to occur
within a few hours of cisplatin administration and typically
resolve in a few days [6].
Several authors have described the presence of seizures
after platinum administration not attributable to PRES,
including two cases of status epilepticus [7–9]. However,
almost all of these patients had laboratory derangements
such as hypomagnesemia or renal insufficiency, or im-
aging abnormalities such as brain metastases, which could
lower the seizure threshold. In the absence of other med-
ical factors that could potentiate them, seizures associated
with platinum chemotherapy appear to be exceedingly
rare. This manuscript describes the only reported case of
nonconvulsive status epilepticus related to cisplatin use in
a cervical cancer patient without other underlying medical
conditions.
Table 1 Timeline of events
Date Key Event
July 2011 Diagnosis of Cervical Cancer




January 2013 Recurrence of disease
January 2013 – October 2013 Treatment for Recurrence
-oxaliplatin/paclitaxel
- tumor-directed radiation
- dendritic cell immunotherapy
- taxane therapy
October 2013 Progression of disease/consultation
at MD Anderson Cancer Center
October 2013 Initiation of topotecan/cisplatin
October 2013 – January 2014 Cycles #1–5 of topotecan/cisplatin
February 2014 Cycle #6 of topotecan/cisplatin
SEIZURE ACTIVITY
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The etiology of platinum-induced CNS toxicity is un-
known, though heavy metal toxicity or demylinization have
been proposed [7]. Overdose of platinum agents can cer-
tainly also cause these disorders. However, reports have
noted CNS toxicity with these drugs at a wide range of
doses and in combination with various chemotherapeutic
agents. As platinum agents do not typically cross the
blood-brain barrier, patients should be protected from
most CNS side effects at doses in the therapeutic range.
It is unclear why this is not true for all patients.
In conclusion, CNS toxicity appears to be a rare but ser-
ious side effect of administration of platinum-containing
drugs. Patients who present with CNS symptoms should
primarily be evaluated for other underlying medical condi-
tions. However, if platinum-based chemotherapy is sus-
pected as the etiology, we suggest the use of alternative
chemotherapeutic regimens in the future.
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